Freshworks Falls Year $7.5: What Investors Should Know
A major fund trimmed Freshworks stock by hundreds of thousands of shares, triggering a 60% year-long drop in the stoc...
Investing
Learn smart investing strategies for stocks, ETFs, bonds, and building long-term wealth.
5,594 articles
Roku Stock Down This Year: Is It Time to Buy?
Roku stock has slipped about 17% year-to-date, even as the company shows improving profitability and optimism for gro...
Core Scientific Stock Year Signals Pivot Data Center Growth
A large new stake underscores Core Scientific's shift toward data center services. This article breaks down the impli...
Stock 150% Million Lifts Hut 8 Stake to New Heights
A bold stake move in Hut 8 has sparked a new conversation about concentration, risk, and opportunity in crypto-relate...
Vail Resorts Skier Visits Dip 20%; Investor Bets Big
Early-season Vail Resorts skier visits slipped about 20%, yet a major investor is stepping in with a multihundred-mil...
Alta Boosts XPEL Stake: A $58M Bet Expands 15.5% Position
Alta Fox quietly increases its XPEL exposure, lifting the stake to about 15.5% after a roughly $58 million purchase. ...
Ishares MSCI Japan Surged: Key Factors for Investors
Japan stocks have been catching the market's eye as ishares msci japan surged. This guide breaks down why now and how...
Resideo Stock Alta Makes Big Bet: What the 66% Move Really Means
A sudden, sizable stake in Resideo Technologies has sent its stock climbing 66%. Alta Fox Capital Management disclose...
Here's Smartest Invest February: S&P 500 Strategy
February can feel like a shifting tide for the S&P 500. This guide shares how to invest smartly this month with a cle...
Illinois Foundation Doubles Down on Shift4 Payments Strategy
A disciplined foundation reshapes its tech-payments exposure by boosting its stake in Shift4 Payments. This article e...
Only Stocks Need Capitalize: 3 AI Winners for 2026
Artificial intelligence is reshaping capital flows across tech and beyond. This guide identifies three core AI infras...
Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...